Loading
A phase 2/3 trial testing Navlimetostat in pancreatic ductal adenocarcinoma, active and no longer recruiting.
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) is a phase 2/3 interventional study registered as NCT07076121, led by Bristol-Myers Squibb, and active but no longer recruiting on the registry. Official title: A Randomised, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion. Planned enrolment is 470 participants (estimated). The study started in 2025-10-23 and primary completion is expected in 2029-05-03. No results have been posted on ClinicalTrials.gov.
Shares Navlimetostat, Bristol Myers Squibb.
Shares Bristol Myers Squibb, Pancreatic ductal adenocarcinoma.
Shares Bristol Myers Squibb, Pancreatic ductal adenocarcinoma.
Shares Bristol Myers Squibb, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Bristol Myers Squibb, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Bristol Myers Squibb, Pancreatic ductal adenocarcinoma.
Shares Navlimetostat, Bristol Myers Squibb, Pancreatic ductal adenocarcinoma.